Literature DB >> 11726606

Uveal melanoma: no expression of HLA-G.

H M Hurks1, M M Valter, L Wilson, I Hilgert, P J van den Elsen, M J Jager.   

Abstract

PURPOSE: To investigate whether uveal melanoma cells express HLA-G, a nonclassical HLA class I molecule that has been shown to be a critical mediator in the inhibition of natural killer (NK) cell-mediated cytolysis.
METHODS: Eleven human uveal melanoma cell lines were analyzed for the expression of HLA-G by flow cytometry, immunocytochemistry, Western blot analysis, and RT-PCR followed by Southern blot analysis. Two HLA-G-specific monoclonal antibodies were used, 87G and MEM-G/1. In addition, HLA-G expression was determined on frozen tissue sections of 17 primary uveal melanomas.
RESULTS: With all HLA-G detection methods, no evidence for HLA-G expression by uveal melanoma cells was found. In contrast, the trophoblast cell line JEG-3 clearly expressed HLA-G transcripts and protein in all cases. Furthermore, interferon-gamma did not induce HLA-G expression in the uveal melanoma cell lines. Notably, all cell lines expressed HLA-E, and this expression was significantly enhanced by interferon-gamma.
CONCLUSIONS: Because none of the uveal melanoma cell lines nor any of the primary uveal melanomas displayed expression of HLA-G, it is unlikely that HLA-G plays a role, direct or indirect, in the modulation of cellular immunity against uveal melanoma tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726606

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  10 in total

1.  Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.

Authors:  Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

Review 2.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

3.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

Review 4.  Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.

Authors:  Anita Q Gomes; Daniel V Correia; Bruno Silva-Santos
Journal:  EMBO Rep       Date:  2007-11       Impact factor: 8.807

Review 5.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

Review 6.  HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Authors:  Zahra Souri; Annemijn P A Wierenga; Arend Mulder; Aart G Jochemsen; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

7.  Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

Authors:  Christiaan van Weeghel; Annemijn P A Wierenga; Mieke Versluis; Thorbald van Hall; Pieter A van der Velden; Wilma G M Kroes; Ulrich Pfeffer; Gregorius P M Luyten; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

Review 8.  Role of Natural Killer Cells in Uveal Melanoma.

Authors:  Asad Javed; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2020-12-09       Impact factor: 6.639

9.  A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1.

Authors:  Richard Apps; Lucy Gardner; Andrew M Sharkey; Nick Holmes; Ashley Moffett
Journal:  Eur J Immunol       Date:  2007-07       Impact factor: 5.532

Review 10.  The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Authors:  Jiji V D Attia; Charlotte E Dessens; Ricky van de Water; Ruben D Houvast; Peter J K Kuppen; Daniëlle Krijgsman
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.